Anthelmintics for people with neurocysticercosis

作者：Abba Katharine^*; Ramaratnam Sridharan; Ranganathan Lakshmi Narasimhan

来源：Cochrane Database of Systematic Reviews, 2010, (3): CD000215.

DOI：10.1002/14651858.CD000215.pub4

• Albendazole [therapeutic use]
• Anticestodal Agents [therapeutic use]
• Brain Diseases [drug therapy
• parasitology]
• Neurocysticercosis [drug therapy]
• Praziquantel [therapeutic use]
• Trichlorfon [therapeutic use]
• Humans

Background
Neurocysticercosis is an infection of the brain by the larval stage of the pork tapeworm. In endemic areas it is a common cause of epilepsy. Anthelmintics (albendazole or praziquantel) may be given to kill the parasites. However, there are potential adverse effects, and the parasites may eventually die without treatment.
Objectives
To assess the effectiveness and safety of anthelmintics for people with neurocysticercosis.
Search strategy
In May 2009 we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2009, Issue 2), MEDLINE, EMBASE, LILACS, and the mRCT.
Selection criteria
Randomized controlled trials comparing anthelmintics with placebo, no anthelmintic, or other anthelmintic regimen for people with neurocysticercosis.
Data collection and analysis
Two authors independently selected trials, extracted data, and assessed each trial's risk of bias. We calculated risk ratios (RR) for dichotomous variables, with 95% confidence intervals (CI). We pooled data from trials with similar interventions and outcomes.
Main results
For viable lesions in children, there were no trials. For viable lesions in adults, no difference was detected for albendazole compared with no treatment for recurrence of seizures (116 participants, one trial); but fewer participants with albendazole had lesions at follow up (RR 0.56, 95% CI 0.45 to 0.70; 192 participants, two trials).
For non-viable lesions in children, seizures recurrence was less common with albendazole compared with no treatment (RR 0.49, 95% CI 0.32 to 0.75; 329 participants, four trials). There was no difference detected in the persistence of lesions at follow up (570 participants, six trials). For non-viable lesions in adults, there were no trials.
In trials including viable, non-viable or mixed lesions (in both children and adults), headaches were more common with albendazole alone (RR 9.49, 95% CI 1.40 to 64.45; 106 participants, two trials), but no difference was detected in one trial giving albendazole with corticosteroids (116 participants, one trial).
Authors' conclusions
In patients with viable lesions, evidence from trials of adults suggests albendazole may reduce the number of lesions. In trials of nonviable lesions, seizure recurrence was substantially lower with albendazole, which is counter-intuitive. It may be that steroids influence headache during treatment, but further research is needed to test this.

• 出版日期2010